Morbidity After Pelvic Exenteration for Gynecological Malignancies A Retrospective Multicentric Study of 230 Patients

被引:65
|
作者
Chiantera, Vito [1 ,2 ,8 ]
Rossi, Martina [1 ,2 ,3 ]
De Iaco, Pierandrea [3 ]
Koehler, Christardt [1 ,2 ]
Marnitz, Simone [4 ]
Fagotti, Anna [5 ]
Fanfani, Francesco [5 ]
Parazzini, Fabio [6 ]
Schiavina, Riccardo [7 ]
Scambia, Giovanni [5 ]
Schneider, Achim [1 ,2 ]
Vercellino, Giuseppe Filiberto [1 ,2 ]
机构
[1] Charite, Dept Gynecol & Gynecol Oncol, Campus Mitte CCM, D-12203 Berlin, Germany
[2] Charite, Campus Benjamin Franklin CBF, D-12203 Berlin, Germany
[3] Alma Mater Studiorum Univ Bologna, Gynecol Oncol Unit, S Orsola Malpighi Hosp, Bologna, Italy
[4] Charite, Dept Radiooncol, Campus Mitte CCM, Campus Virchow CVK, D-12203 Berlin, Germany
[5] Univ Cattolica Sacro Cuore, Gynecol Oncol Unit, I-00168 Rome, Italy
[6] Univ Milan, Fdn Policlin Milano, Milan, Italy
[7] Alma Mater Studiorum Univ Bologna, Dept Urol, S Orsola Malpighi Hosp, Bologna, Italy
[8] Univ Cattolica Sacro Cuore, Gynecol Oncol Unit, Campobasso, Italy
关键词
Pelvic exenteration; Morbidity; Mortality; Gynecological malignancies; URINARY-DIVERSION; SUPRALEVATOR; SURVIVAL;
D O I
10.1097/IGC.0000000000000011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective Our study purpose was to evaluate morbidity and postoperative mortality in patients who underwent pelvic exenteration (PE) for primary or recurrent gynecological malignancies. Methods We identified 230 patients who underwent PE, referred to the gynecological oncology units of 4 institutions: Charite University in Berlin, Friedrich-Schiller University in Jena, S. Orsola-Malpighi University in Bologna, and Catholic University in Rome and in Campobasso. Results The median age was 55 years. The tumor site was the cervix in 177 patients, the endometrium in 28 patients, the vulva in 16 patients, and the vagina in 9 patients. Sixty-eight anterior, 31 posterior, and 131 total PEs were performed in 116 women together with hysterectomy. A total of 82.6% of the patients required blood transfusion. The mean operative time was 446 (95-970) minutes, and the median hospitalization was 24 (7-210) days. We noted a major complication rate of 21.3% (n = 49). We registered 7 perioperative deaths (3%) calculated within 30 days. The operation was performed within clear margins in 166 patients (72.2%). The overall mortality rate depending on tumor site at the end of the study was 75% for vulvar cancer, 57.6% for cervical cancer, 55.6% for vaginal cancer, and 53.6% for endometrial cancer. Conclusions Although an important effort for surgeons and for patients, PE remains a therapeutic option with an acceptable complication rate and postoperative mortality. A strict selection of patients is mandatory to reach adequate surgical and oncologic outcomes.
引用
收藏
页码:156 / 164
页数:9
相关论文
共 50 条
  • [31] Utilization and perioperative outcome of minimally invasive pelvic exenteration in gynecologic malignancies: A national study in the United States
    Matsuo, Koji
    Matsuzaki, Shinya
    Mandelbaum, Rachel S.
    Kanao, Hiroyuki
    Chang, Erica J.
    Klar, Maximilian
    Roman, Lynda D.
    Wright, Jason D.
    GYNECOLOGIC ONCOLOGY, 2021, 161 (01) : 39 - 45
  • [32] Pelvic Exenteration for Recurrent Vulvar Cancer: A Retrospective Study
    Classen-von Spee, Sabrina
    Baransi, Saher
    Fix, Nando
    Rawert, Friederike
    Luengas-Wuerzinger, Veronica
    Lippert, Ruth
    Bonin-Hennig, Michelle
    Mallmann, Peter
    Lampe, Bjoern
    CANCERS, 2024, 16 (02)
  • [33] Pelvic exenteration for vulvar cancer: Postoperative morbidity and oncologic outcome- A single center retrospective analysis
    Valstad, H.
    Eyjolfsdottir, B.
    Wang, Y.
    Kristensen, G. B.
    Skeie-Jensen, T.
    Lindemann, K.
    EJSO, 2023, 49 (09):
  • [34] Pelvic exenteration without external urinary or fecal diversion in gynecological cancer patients
    Ungar, L
    Palfalvi, L
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (01) : 364 - 368
  • [35] Minimally invasive pelvic exenteration for gynaecological malignancies: the challenge of patients' selection
    Bizzarri, N.
    Chiantera, V.
    Loverro, M.
    Ercoli, A.
    Vizzielli, G.
    Scambia, G.
    FACTS VIEWS AND VISION IN OBGYN, 2023, 15 (03): : 193 - 196
  • [36] Quality of life after pelvic exenteration for gynecologic cancer: Findings from a qualitative study
    Nelson, Ashley M.
    Albizu-Jacob, Alexandra
    Fenech, Alyssa L.
    Chon, Hye Sook
    Wenham, Robert M.
    Donovan, Kristine A.
    PSYCHO-ONCOLOGY, 2018, 27 (10) : 2357 - 2362
  • [37] Comparation between the Bricker ileal conduit vs double-barrelled wet colostomy after pelvic exenteration for gynaecological malignancies
    Lago, Victor
    Aramendi, Tamara Pradillo
    Segarra-Vidal, Blanca
    Padilla-Iserte, Pablo
    Matute, Luis
    Gurrea, Marta
    Pontones, Jose Luis
    Delgado, Francisco
    Domingo, Santiago
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2023, 282 : 140 - 145
  • [38] Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies
    Urh, Anze
    Soliman, Pamela T.
    Schmeler, Kathleen M.
    Westin, Shannon
    Frumovitz, Michael
    Nick, Alpa M.
    Fellman, Bryan
    Urbauer, Diana L.
    Ramirez, Pedro T.
    GYNECOLOGIC ONCOLOGY, 2013, 129 (03) : 580 - 585
  • [39] Retrospective study of combined pelvic exenteration in the treatment of primary and recurrent pelvic malignant tumors
    Li, Changzheng
    Li, Zhenyu
    Zhang, Jiachen
    Zhang, Xijie
    Siesto, Gabriele
    Li, Sen
    Ma, Pengfei
    Zhang, Junli
    Li, Zhi
    Zhao, Yuzhou
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (01) : 299 - 311
  • [40] Prospective Assessment of First-Year Quality of Life After Pelvic Exenteration for Gynecologic Malignancy: A French Multicentric Study
    A. Martinez
    T. Filleron
    P. Rouanet
    P. Méeus
    E. Lambaudie
    J. M. Classe
    F. Foucher
    F. Narducci
    S. Gouy
    F. Guyon
    F. Marchal
    E. Jouve
    P. E. Colombo
    A. Mourregot
    M. Rivoire
    N. Chopin
    G. Houvenaeghel
    I. Jaffre
    J. Leveque
    V. Lavoue
    E. Leblanc
    P. Morice
    E. Stoeckle
    J. L. Verheaghe
    D. Querleu
    G. Ferron
    Annals of Surgical Oncology, 2018, 25 : 535 - 541